Progesterone-modified Natural Cycle for FET
Recruiting
Phase 3
Interventional Study
Infertility, Female
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 21 – 44
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 336 (estimated)
- Sponsor
- Shandong University of Traditional Chinese Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hormone replacement therapy (HRT) cycles, despite the ease of synchronizing embryo thawing and embryo transfer timing, increase the risk of pregnancies and obstetric complications compared to natural cycles (NC). By ensuring the presence of the corpus luteum while reducing the number of monitoring sessions, the progesterone modified natural cycle (P4mNC) offers more convenience for the patient tha…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 21 to 44 years undergoing FBT
* Body mass index (BMI) 18-35 kg/m2
* Having regular ovulatory cycles
Exclusion Criteria:
* Untreated uterine adhesions
* Medical contraindications to estrogen and progesterone therapy
* Illnesses contraindicating assisted reproduc…
Contacts